Altamira Therapeutics Wins China Approval for Bentrio Nasal Spray
I'm PortAI, I can summarize articles.
Altamira Therapeutics Ltd. announced that its associate company, Altamira Medica, received marketing approval from China's NMPA for Bentrio® nasal spray, used to treat allergic rhinitis. This approval allows Nuance Pharma, their distribution partner, to market Bentrio in Mainland China, where nearly 200 million people suffer from allergic rhinitis. The news was originally published by Altamira Therapeutics via ACCESS Newswire on December 19, 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments